These data support current guidelines and should prompt oncologists to consider including everolimus in the therapeutic strategy for patients with advanced HR+, HER2− breast cancer, particularly from the third line onwards, while the benefit–risk balance must be assessed on a case-by-case basis. The gene discussed is ERBB2; the disease is breast carcinoma.